Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reaffirmed by Jefferies Group in a research report issued on Wednesday.
The analysts wrote, “Impella secured approval in Japan; the late summer approval was largely on target. The label is somewhat different than in the US: Impella is indicated for drug-resistant acute heart failure, but not prophylactic or elective use.””
A number of other research analysts also recently issued reports on the company. Citigroup Inc. reduced their price target on Amgen from $175.00 to $172.00 and set a “neutral” rating on the stock in a report on Wednesday. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a report on Wednesday. Goldman Sachs Group Inc. restated a “buy” rating and set a $206.00 price target (up previously from $204.00) on shares of Amgen in a report on Tuesday. BMO Capital Markets restated an “outperform” rating and set a $190.00 price target on shares of Amgen in a report on Thursday, September 22nd. Finally, Cowen and Company restated a “buy” rating on shares of Amgen in a report on Monday, September 19th. One analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Amgen currently has an average rating of “Buy” and an average price target of $185.06.
Shares of Amgen (NASDAQ:AMGN) opened at 165.45 on Wednesday. The stock has a 50 day moving average price of $171.84 and a 200 day moving average price of $160.86. The stock has a market capitalization of $123.82 billion, a P/E ratio of 16.93 and a beta of 0.87. Amgen has a 52 week low of $135.64 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.57 earnings per share. On average, equities research analysts expect that Amgen will post $11.36 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were issued a $1.00 dividend. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a yield of 2.42%. Amgen’s payout ratio is currently 40.90%.
In related news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. Oakworth Capital Inc. raised its position in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares during the last quarter. Valley National Advisers Inc. raised its position in shares of Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock worth $109,000 after buying an additional 33 shares during the last quarter. Glassman Wealth Services raised its position in shares of Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock worth $110,000 after buying an additional 600 shares during the last quarter. Integrated Wealth Management raised its position in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares during the last quarter. Finally, Delta Asset Management LLC TN raised its position in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.